Login
Super Investors Bain Capital Life Sciences Investors, LLC
BC

Bain Capital Life Sciences Investors, LLC

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$1.49B
Positions
23
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (36 quarters reported)

$1.77B $152M
Q4 17 Q4 19 Q4 21 Q4 23 Q4 25 Q3 26

$152M in Q4 2017 → $1.49B now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Kailera Therapeutics Inc 17.3% Unchanged 22,583,268 $258M
Heartflow Inc 14.9% Trimmed 47% 4,448,158 $221M
Adarx Pharmaceuticals Inc 9.0% New 6,728,970 $134M
Alkermes PLC 8.6% Added 63% 3,150,985 $128M
NP Newamsterdam Pharma Company 6.2% Trimmed 0.0% 3,806,559 $92.6M
Savara Inc 6.1% Unchanged 17,600,621 $90.8M
Tarsus Pharmaceuticals Inc 5.8% New 1,096,141 $86.2M
Pharvaris N V 5.2% Trimmed 7.5% 2,475,509 $76.9M
Solid Biosciences Inc 4.8% Unchanged 9,808,819 $70.9M
Olema Pharmaceuticals Inc 4.1% Unchanged 7,085,249 $61.2M
Hemab Therapeutics Holdings Inc 3.4% Unchanged 1,650,000 $50.9M
Cabaletta Bio Inc 2.7% Added 23% 21,209,188 $40.7M
Freenome Inc 2.5% New 2,365,459 $37.3M
Dyne Therapeutics Inc 2.1% New 1,900,000 $30.6M
C4 Therapeutics Inc 1.6% Unchanged 7,171,910 $23.9M
X4 Pharmaceuticals Inc 1.6% Unchanged 7,967,454 $23.1M
Annexon Inc 1.3% Unchanged 4,437,731 $18.8M
Atea Pharmaceuticals Inc 0.7% Unchanged 2,075,639 $10.8M
Disc Medicine Inc 0.6% Unchanged 141,234 $9.25M
Kyverna Therapeutics Inc 0.6% Trimmed 55% 1,312,000 $8.92M
Rapid Micro Biosystems Inc 0.6% Unchanged 8,434,560 $8.69M
Xilio Therapeutics Inc 0.4% Unchanged 664,021 $6.01M
NP Newamsterdam Pharma Company 0.1% Unchanged 99,999 $1.26M

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
Heartflow Inc Trimmed −4,000,000 −$199M 14.9%
Adarx Pharmaceuticals Inc New +6,728,970 +$134M 9.0%
Tarsus Pharmaceuticals Inc New +1,096,141 +$86.2M 5.8%
Alkermes PLC Added +1,213,047 +$49.2M 8.6%
Freenome Inc New +2,365,459 +$37.3M 2.5%
Dianthus Therapeutics Inc Exited −362,470 −$35.3M —
Dyne Therapeutics Inc New +1,900,000 +$30.6M 2.1%
Kyverna Therapeutics Inc Trimmed −1,573,000 −$10.7M 0.6%
Cabaletta Bio Inc Added +3,967,743 +$7.62M 2.7%
Pharvaris N V Trimmed −200,000 −$6.21M 5.2%

Showing the 10 largest of 12 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
Kailera Therapeutics Inc New +22,583,268 +$498M 29.6%
NP Newamsterdam Pharma Company Trimmed −3,500,000 −$119M 7.7%
Alkermes PLC Added +1,327,938 +$69.6M 6.0%
Hemab Therapeutics Holdings Inc New +1,650,000 +$60.6M 3.6%
Heartflow Inc Trimmed −2,000,000 −$58.7M 14.7%
Centessa Pharmaceuticals Exited −635,000 −$25.2M —
Cabaletta Bio Inc Added +7,564,320 +$23.5M 3.2%
Olema Pharmaceuticals Inc Trimmed −387,989 −$4.85M 5.3%
Annexon Inc Trimmed −774,943 −$4.42M 1.5%
Kyverna Therapeutics Inc Trimmed −225,000 −$2M 1.5%

Showing the 10 largest of 12 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
Heartflow Inc Trimmed −2,000,000 −$48.7M 22.9%
Dianthus Therapeutics Inc Trimmed −381,122 −$32M 2.7%
Centessa Pharmaceuticals New +635,000 +$25.2M 2.3%
Alkermes PLC New +610,000 +$21.6M 1.9%
Olema Pharmaceuticals Inc Trimmed −1,035,403 −$15.4M 10.0%
Solid Biosciences Inc Added +1,897,150 +$13.7M 6.4%
Mersana Therapeutics Inc Exited −346,545 −$10M —
Disc Medicine Inc New +141,234 +$9.03M 0.8%
Tango Therapeutics Inc Exited −653,493 −$5.79M —
Xilio Therapeutics Inc New +664,021 +$5.58M 0.5%

Showing the 10 largest of 15 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
Cidara Therapeutics Inc Exited −3,020,990 −$289M —
NP Newamsterdam Pharma Company Trimmed −3,412,544 −$120M 19.6%
Olema Pharmaceuticals Inc Added +1,664,687 +$41.6M 16.3%
Upstream Bio Inc Trimmed −1,109,994 −$30.1M 2.8%
Dianthus Therapeutics Inc Trimmed −572,300 −$23.6M 2.3%
X4 Pharmaceuticals Inc Added +5,530,866 +$22.1M 2.4%
Tango Therapeutics Inc Trimmed −2,058,515 −$18.2M 0.4%
C4 Therapeutics Inc Added +6,060,000 +$11.6M 1.0%
Pharvaris N V Trimmed −379,194 −$10.5M 6.0%
Kyverna Therapeutics Inc Trimmed −258,370 −$2.43M 2.2%

Showing the 10 largest of 13 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
Heartflow Inc New +12,448,158 +$419M 27.8%
Nuvalent Inc Exited −1,447,267 −$110M —
Cidara Therapeutics Inc Added +520,310 +$49.8M 19.2%
Dianthus Therapeutics Inc Trimmed −1,166,358 −$45.9M 3.4%
Disc Medicine Inc Exited −583,500 −$30.9M —
X4 Pharmaceuticals Inc Added +1,872,729 +$6.4M 0.6%
Pharvaris N V Trimmed −122,106 −$3.05M 5.3%
Mersana Therapeutics Inc New +346,545 +$2.69M 0.2%
Mersana Therapeutics Inc Exited −8,663,673 −$2.56M —
Invivyd Inc Exited −1,799,595 −$1.29M —

Showing the 10 largest of 11 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Cidara Therapeutics Inc Added +1,797,600 +$87.6M 15.2%
Disc Medicine Inc Trimmed −400,000 −$21.2M 3.9%
Cabaletta Bio Inc Added +6,916,237 +$10.5M 1.8%
X4 Pharmaceuticals Inc Exited −16,915,784 −$4M —
Dianthus Therapeutics Inc Trimmed −207,457 −$3.86M 5.8%
Upstream Bio Inc Added +144,216 +$1.58M 3.4%
X4 Pharmaceuticals Inc New +563,859 +$1.07M 0.1%
Nautilus Biotechnology Inc Exited −1,072,421 −$923K —

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
Solid Biosciences Inc Added +3,877,087 +$14.3M 4.3%
Savara Inc Added +3,035,164 +$8.41M 7.2%
Olema Pharmaceuticals Inc Trimmed −626,260 −$2.35M 3.8%
Marinus Pharmaceuticals Inc Exited −2,693,380 −$1.44M —
Syros Pharmaceuticals Inc Exited −2,750,151 −$632K —
Nautilus Biotechnology Inc Trimmed −686,579 −$591K 0.1%

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
Nuvalent Inc Trimmed −1,250,000 −$97.9M 13.3%
Disc Medicine Inc Trimmed −812,235 −$51.5M 7.3%
Olema Pharmaceuticals Inc New +7,470,214 +$43.6M 5.1%
Upstream Bio Inc New +2,295,322 +$37.7M 4.4%
Annexon Inc Trimmed −3,200,679 −$16.4M 3.2%
Dianthus Therapeutics Inc Trimmed −323,716 −$7.06M 6.9%
NP Newamsterdam Pharma Company Added +245,197 +$6.3M 32.4%
Nautilus Biotechnology Inc Trimmed −241,000 −$405K 0.3%

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support